The 3PC Trial (Intraductal Papillary Mucinous Neoplasm) - Clinical Trial
Email to Participate
elizabeth.bronson@duke.edu
What is the Purpose of this Study?
Treatment
If you choose to join this study, you will:
- Be randomized to Group 1 or Group 2
-- Group 1 will get the study drug (Sulindac)
-- Group 2 will get a placebo (harmless sugar pill)
Both groups will have:
- CT scans (body scan)
- Endoscopy's (a way to look at your digestive tract)
- Collection of cyst fluid from the pancreas
What is the Condition Being Studied?
Objective
Intraductal Papillary Mucinous Neoplasms (IPMN)
Who Can Participate in the Study?
Key Eligibility
- Men and women 21-85 years old
- Diagnosed with high-risk intraductal papillary mucinous neopolasm (IPMN)
Age Group
Adults
What is Involved?
Description
We are doing this study to learn more about how the study drug, Sulindac, effects people with high risk intraductal papillary mucinous neoplasms (IPMN). The study drug (Sulindac) is a non-steroidal, anti-inflammatory medicine commonly called an NSAID.
Study Details
Full Title
The Prevention of Progression to Pancreatic Cancer Trial (The 3P-C Trial)
Principal Investigator
Gastrointestinal Surgeon
Protocol Number
IRB:
PRO00103684
NCT:
NCT04207944
Phase
Phase
II
ClinicalTrials.gov
View on ClinicalTrials.gov
Enrollment Status
Open for Enrollment
Participate